Thetis Pharmaceuticals LLC
1 known investors
Thetis is a clinical-stage pharmaceutical company developing oral TP-317, a first-in-class drug for treating inflammatory bowel disease and solid tumors by activating BLT1 to restore tissue and immune homeostasis.
BiotechMedical Devices
Investors · 1
In the news
- Thetis Pharmaceuticals Presents New Preclinical and Clinical Data forTP-317 at DDW 2025businesswire.com · 2025
- Thetis Pharmaceuticals Secures an Additional $8.975 Million in Program-Related Investment Funds from the Helmsley Charitable Trust to Advance TP-317, an Oral BLT1 Agonist, into a Phase 1b Trial in Ulcerative Colitis Patientsbusinesswire.com · 2025
- Thetis Pharmaceuticals Announces Appointment of Fabio Cataldi, M.D., to Board of Managers and Scientific Advisory Boardbusinesswire.com · 2024
- Thetis Pharmaceuticals Progressing to Clinic with a Phase 1a Trial of TP-317, an Oral Agonist of BLT1, in Healthy Subjects — Thetis Pharmaceuticalsthetispharma.com · 2024
- Thetis Pharmaceuticals Receives $1.9 Million Fast-Track NIH Grant to Advance Novel Inflammatory Bowel Disease Drug Pipeline Toward Clinical Investigationglobenewswire.com · 2018
- Thetis Pharmaceuticals - Carter Morse & Goodrichcartermorse.com · 2015